Following the IND clearance, company plans to initiate P-Ia trial evaluating safety, tolerability, PK & PD in healthy volunteers (n=64 in 5 SAD & 3 MAD cohorts) in Q2’24, whereas topline data is anticipated by H2’24
Upon successful completion of P-Ia part of study, the company will initiate P-Ib part in moderate-to-severe plaque Pso patients & adult-onset RA with topline data in H2’25
VYN202 (BD2-selective BET inhibitor) attained consistent reduction in pro-inflammatory and disease-related biomarkers with improvements in disease severity in preclinical studies
Ref: VYNE Therapeutics | Image: VYNE Therapeutics
Related News:- VYNE Reports Results of FMX114 in P-Ib Portion of a P-Ib/IIa Trial for the Treatment of Mild-to-Moderate Atopic Dermatitis
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
